Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study

Kim, Jong Gwang; Sohn, Sang Kyun; Chae, Yee Soo; Cho, Yoon Young; Yang, Deok Hwan; Lee, Je‐Jung; Kim, Hyeoung-Joon; Shin, Ho Jin; Chung, Joo Seop; Cho, Goon Jae; Lee, Won-Sik; Joo, Young-Don; Sohn, Chang-Hak; Oh, Suk Joong

doi:10.1007/s00280-007-0469-9

Cited by 104 publications

(47 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although our ORR seems similar to other studies using various regimen [15-20, 23-27, 42-44, 53], the result needs to be interpreted carefully because other similar studies using alemtuzumab-CHOP have the highest number of PTCL, NOS cases among their study subjects [42,43], whereas no PTCL, NOS subject was recruited into our study during the study period.…”

Section: Discussionsupporting

confidence: 79%

“…In one of the alemtuzumab-CHOP trials of using oral acyclovir 400 mg twice daily as CMV prophylaxis, 15 episodes of CMV reactivation were observed in the total of 24 subjects [43]. Another alemtuzumab-CHOP study which used oral acyclovir 600 mg twice daily had CMV reactivation in five out of the total of 20 patients [42]. Our study used lower dose of oral acyclovir, which was 200 mg thrice daily.…”

Section: Discussionmentioning

confidence: 67%

“…Larger combination trials on alemtuzumab with CHOP [42][43][44] or EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, dozorubicin) [45] are still ongoing.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

Kuan

Chang

Lau

et al. 2011

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

We report our experience in using six cycles of hyperCVAD in combination with alemtuzumab for the treatment of aggressive T-cell and NK/T-cell neoplasms. Seven females and six males with the median age of 41 (range 18-60) diagnosed with T-cell acute lymphoblastic lymphoma and peripheral T-cell and NK/T-cell neoplasms (n PTCL = 6, n T-cell ALL = 3, n NK/T-cell neoplasms = 4) from 2006 to 2008 were treated with alemtuzumab-hyperCVAD regimen. A total of nine patients (69%) responded to the regimen, with seven achieved complete remission and two achieved partial remission. The median progression free survival and overall survival duration among the responders with complete remission were 12.9 and 24.9 months respectively. The incidence of relapse among the responders was 44% and the overall survival rate was 23%. Only four (31%) patients completed the six cycles of alemtuzumab-hyperCVAD. Others were stopped earlier due to progressive disease (n = 2), cytomegalovirus (CMV) reactivation and/or disease (n = 3), death not due to disease (n = 2), and patient's refusal to continue alemtuzumab (n = 2). The incidence of death not due to disease, CMV reactivation and recurrent CMV reactivation were 50, 50 and 17%, respectively. This study shows that alemtuzumab in combination with hyperCVAD regimen is a feasible regimen but with high toxicity. The toxicity might be reduced with the incorporation of filgrastim and use of valganciclovir as CMV prophylaxis.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 67%

See 1 more Smart Citation

The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

Kuan

Chang

Lau

et al. 2011

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

“…26 AL was given in combination with CHOP at various schedules and doses; the achievement of CR varied from 65 to 70%, although with a quite limited advantage in terms of EFS. 6,7,8 Despite the absence of phase III trials, the consolidation of response with autoSCT is commonly employed in the clinical practice and the evidence is mostly derived from phase II studies. The most recent prospective trials of up-front autoSCT reported a favorable outcome with 3-year PFS and OS ranging from 36 to 48% and from 48 to 56%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…However, the 2-year EFS was not improved, suggesting that a consolidation was probably required. 6,7,8 Therapy intensification with up-front autologous stem cell transplantation (autoSCT) was explored in phase II studies and resulted in a 3-year EFS ranging from 30 to 50%. 9,10,11,12 Recently, the Nordic Lymphoma group reported the results of up-front autoSCT following six courses of CHOEP-14.…”

Section: Intensified Chemo-immunotherapy With or Without Stem Cell Trmentioning

confidence: 99%

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma

et al. 2014

View full text Add to dashboard Cite

The definitive version is available at: La versione definitiva è disponibile alla URL: [http://www.nature.com.offcampus.dam.unito.it/leu/journal/v28/n9/full/leu201479 a.html] Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral Tcell lymphoma AbstractPeripheral T-cell lymphomas (PTCLs) receiving conventional treatment have a poor clinical outcome. We conducted a phase II study to evaluate the feasibility and efficacy of chemoimmunotherapy in young ( 60 years old, Clin A study) and elderly (>60 and 75 years old, Clin B study) patients with newly diagnosed PTCL. Clin A patients (n=61) received two courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone)-21 with alemtuzumab (AL, 30 mg) followed by two courses of high-dose chemotherapy. On the basis of donor availability, patients in response received allogeneic (allo) or autologous (auto) stem cell transplantation (SCT). Clin B patients (n=25) received six courses of CHOP-21 and AL (10 mg). Clin A responding patients were 38 of 61 (62%) and received alloSCT (n=23) or autoSCT (n=14); one complete remission (CR) patient was not transplanted. At a median follow-up of 40 months, the 4-year overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) rates were 49, 44 and 65%, respectively. In Clin B study, the response rate was 72%. At a median follow-up of 48 months, the 4-year OS, PFS and DFS rates were 31, 26 and 44%, respectively. In conclusion, front-line alloSCT or autoSCT is effective in prolonging DFS in young patients; AL in elderly improved response with no survival benefit.

show abstract

Standard Front‐line Therapies

Koch¹,

Truempe²

2021

The Peripheral T‐Cell Lymphomas

View full text Add to dashboard Cite

Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study

Cited by 104 publications

References 18 publications

The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma

Standard Front‐line Therapies

Contact Info

Product

Resources

About